CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PRODUCT KNOW-HOW LICENSE AGREEMENT among SANOFI BRISTOL-MYERS SQUIBB COMPANY and SANOFI PHARMA BRISTOL- MYERS SQUIBB dated as...Product Know-How License Agreement • August 17th, 2009 • Bristol Myers Squibb Co • Pharmaceutical preparations • New York
CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION TERRITORY A ALLIANCE SUPPORT AGREEMENT between SANOFI and BRISTOL-MYERS SQUIBB COMPANY dated as of January 1, 1997Alliance Support Agreement • August 17th, 2009 • Bristol Myers Squibb Co • Pharmaceutical preparations • New York
TERRITORY A ALLIANCE SUPPORT AGREEMENT dated as of January 1, 1997 between Sanofi, a socièté anonyme organized under the laws of the French Republic (“Sanofi”), and Bristol-Myers Squibb Company, a Delaware corporation (“BMS” and, together with Sanofi, the “Parties” and, individually, each a “Party”);
Amendment No. 1 to the Territory B Alliance Support AgreementTerritory B Alliance Support Agreement • August 17th, 2009 • Bristol Myers Squibb Co • Pharmaceutical preparations
This AMENDMENT No. 1 (this “Amendment No. 1”), dated as of October 17, 2001 and effective as of October 1, 2001 (the “Effective Date”) to the Territory B Alliance Support Agreement dated as of January 1, 1997 is hereby made by and between Sanofi-Synthélabo, a société anonyme organized and existing under the laws of the French Republic (“SSBO”) as the successor in interest to Sanofi, a société anonyme organized under the laws of the French Republic, and Bristol-Myers Squibb Company, a Delaware corporation (“BMS” and, together with SSBO, the “Parties” and, individually, each a “Party”).
CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION AMENDMENT NO. 5 TO THE RESTATED DEVELOPMENT AND COMMERCIALIZATION COLLABORATION AGREEMENTRestated Development and Commercialization Collaboration Agreement • August 17th, 2009 • Bristol Myers Squibb Co • Pharmaceutical preparations
THIS AMENDMENT NO. 5 (“Amendment”) to that certain Restated Development and Commercialization Collaboration Agreement dated October 23, 2001 (“Restated Agreement”), effective as of April 4, 2009 (“Amendment Effective Date”), is by and between Otsuka Pharmaceutical Co., Ltd. (“Otsuka”), a corporation organized and existing under the laws of Japan, having a principal place of business at Shinagawa Grand Central Tower, 2-16-4 Konan, Minato-Ku, Tokyo, 108-8242 Japan, and Bristol-Myers Squibb Company (“BMS”), a corporation organized and existing under the laws of Delaware, having a principal place of business at Route 206 and Province Line Road, Princeton, New Jersey, 08540, USA.
CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION CLOPIDOGREL INTELLECTUAL PROPERTY LICENSE AND SUPPLY AGREEMENT between SANOFI and SANOFI PHARMA BRISTOL- MYERS SQUIBB dated as...Intellectual Property License and Supply Agreement • August 17th, 2009 • Bristol Myers Squibb Co • Pharmaceutical preparations • New York
CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION CLOPIDOGREL INTELLECTUAL PROPERTY LICENSE AND SUPPLY AGREEMENT between SANOFI and BRISTOL-MYERS SQUIBB SANOFI PHARMACEUTICALS...Intellectual Property License and Supply Agreement • August 17th, 2009 • Bristol Myers Squibb Co • Pharmaceutical preparations • New York
CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION RESTATED DEVELOPMENT AND COMMERCIALIZATION COLLABORATION AGREEMENT between OTSUKA PHARMACEUTICAL CO., LTD. and BRISTOL-MYERS...Development and Commercialization Collaboration Agreement • August 17th, 2009 • Bristol Myers Squibb Co • Pharmaceutical preparations • Delaware
This Restated Development and Commercialization Collaboration Agreement (this “Agreement”) is made and entered into as of October 23, 2001 (the “Restated Agreement Date”), by and between OTSUKA PHARMACEUTICAL CO., LTD. (“Otsuka”), a corporation organized and existing under the laws of Japan, having a principal place of business at 2-9, Kanda Tsukasa-cho, Chiyoda-ku, Tokyo, Japan, and BRISTOL-MYERS SQUIBB COMPANY (“BMS”), a corporation organized and existing under the laws of Delaware, having a principal place of business at Route 206 and Province Line Road, Princeton, New Jersey 08540, USA. This Agreement amends and restates that certain Development and Commercialization Collaboration Agreement between Otsuka and BMS dated September 20, 1999. The Effective Date of the Agreement, as amended and restated here, remains September 20, 1999.
Amendment No. 1 to the Territory A Alliance Support AgreementTerritory a Alliance Support Agreement • August 17th, 2009 • Bristol Myers Squibb Co • Pharmaceutical preparations
This AMENDMENT No. 1 (this “Amendment No. 1”). dated as of October 17, 2001 and effective as of October 1, 2001 (the “Effective Date”) to the Territory A Alliance Support Agreement dated as of January 1, 1997 is hereby made by and between Sanofi-Synthélabo, a société anonyme organized and existing under the laws of the French Republic (“SSBO”) as the successor in interest to Sanofi, a société anonyme organized under the laws of the French Republic, and Bristol-Myers Squibb Company, a Delaware corporation (“BMS” and, together with SSBO, the “Parties” and, individually, each a “Party”).
CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PARTNERSHIP AGREEMENT OF BRISTOL-MYERS SQUIBB SANOFI PHARMACEUTICALS HOLDING PARTNERSHIP between SANOFI PHARMACEUTICALS, INC....Partnership Agreement • August 17th, 2009 • Bristol Myers Squibb Co • Pharmaceutical preparations • Delaware
PARTNERSHIP AGREEMENT dated as of January 1, 1997 between Sanofi Pharmaceuticals, Inc., a Delaware corporation (“Sanofi Partner”) and an indirect wholly owned subsidiary of Sanofi, a société anonyme organized under the laws of the French Republic (“Sanofi”), and Bristol-Myers Squibb Company Investco, Inc. (“BMS Partner” and, together with Sanofi Partner, the “Partners” and, individually, each a “Partner”), a Delaware corporation and a direct wholly owned subsidiary of Bristol-Myers Squibb Company, a Delaware corporation (“BMS”).
CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION AMENDMENT NO. 3 TO THE RESTATED DEVELOPMENT AND COMMERCIALIZATION COLLABORATION AGREEMENTRestated Development and Commercialization Collaboration Agreement • August 17th, 2009 • Bristol Myers Squibb Co • Pharmaceutical preparations
THIS AMENDMENT NO. 3 (“Amendment”) to that certain Restated Development and Commercialization Collaboration Agreement dated October 23, 2001 (“Restated Agreement”), is made and entered into as of September 25, 2006 (“3rd Amendment Effective Date”), by and between Otsuka Pharmaceutical Co., Ltd. (“Otsuka”), a corporation organized and existing under the laws of Japan, having a principal place of business at 2-9, Kanda Tsukasa-cho, Chiyoda-ku, Tokyo, 101-8535 Japan, and Bristol-Myers Squibb Company (“BMS”), a corporation organized and existing under the laws of Delaware, having a principal place of business at 345 Park Avenue, New York, New York 10154, USA.
